SEC Form 4/A · accession 0001179110-17-012626
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Srinivas Akkaraju
Director
Period of report
Jun 8, 2017
Accepted (ET)
Sep 22, 2017 · 5:19 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $14.62 | Jun 8, 2017 | A | 22,000 | A | — | Jun 7, 2027 | Common Stock | 22,000 | 22,000 | D |
Explanation of responses
- F11. The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the third anniversary of the date of the award, subject to Dr. Akkaraju's continued service as a director through each applicable vesting date.
- F2This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person.